Barclays
ABVX icon

Barclays’s Abivax ABVX Stock Holding History

Barclays’s Portfolio ABVX Stock Details ABVX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$7.95M Buy
80,292
+75,393
+1,539% +$9.09M ﹤0.01% 1778
2026
Q2 		$653K Sell
4,899
-85,876
-95% -$9.7M ﹤0.01% 3059
2026
Q1 		$10.1M Sell
90,775
-218,014
-71% -$25.8M ﹤0.01% 1447
2025
Q4 		$41.6M Buy
308,789
+232,447
+304% +$25.4M 0.01% 872
2025
Q3 		$6.48M Sell
76,342
-37,049
-33% -$2.27M ﹤0.01% 2002
2025
Q2 		$867K Buy
113,391
+111,913
+7,572% +$729K ﹤0.01% 3436
2025
Q1 		$9.24K Buy
1,478
+383
+35% +$2.59K ﹤0.01% 4877
2024
Q4 		$8.02K Buy
+1,095
New +$10.1K ﹤0.01% 5019

Other funds holding ABVX

Helikon Investments
Helikon Investments London, United Kingdom $3.52B AUM 36.83% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $30.6B AUM 42.55% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.96T AUM 27.49% 1-Year Est. Return
Nationale-Nederlanden Powszechne Towarzystwo Emerytalne
Nationale-Nederlanden Powszechne Towarzystwo Emerytalne Warszawa, Poland $2.08B AUM 157.4% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $72.4B AUM 31.32% 1-Year Est. Return
Two Seas Capital
Two Seas Capital Rye, New York $8.68B AUM 78.08% 1-Year Est. Return
BlackRock
BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $106B AUM 32.76% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $123B AUM 30.05% 1-Year Est. Return
Ensign Peak Advisors
Ensign Peak Advisors Salt Lake City, Utah $60.6B AUM 33.98% 1-Year Est. Return

Barclays's ABVX Position: Q3 2026 in Review

Barclays increased its Abivax (ABVX) stake by 1,539% in Q3 2026, buying an estimated $9.09M and bringing the position to 80,292 shares worth $7.95M. The position accounts for ﹤0.01% of the portfolio, ranked #1778.

Barclays first reported a position in ABVX in Q4 2024 and has held it in 8 quarters since. The position peaked at $41.6M in Q4 2025. 211 funds tracked by Wall St. Rank hold ABVX as of Q3 2026.

  • Barclays held 80,292 shares of Abivax worth $7.95M as of Q3 2026.
  • Barclays bought 75,393 Abivax shares in Q3 2026, an estimated $9.09M.
  • Abivax made up ﹤0.01% of Barclays's portfolio in Q3 2026, its #1778 holding.
  • Barclays first reported a position in Abivax in Q4 2024 and has held it in 8 quarters since.
  • Barclays's Abivax position peaked at $41.6M in Q4 2025.
  • 211 funds tracked by Wall St. Rank held Abivax as of Q3 2026.

Based on Barclays's 13F filing for Q3 2026, filed 6 Nov 2026.